The online version of this article (https://doi.org/10.1007/s13555-018-0236-3) contains supplementary material, which is available to authorized users.
To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.6061838.
The aim of this study was to compare the public health impact of introducing two herpes zoster (HZ) vaccines into the vaccination programs for the Japanese population aged ≥ 50 years: a single-dose Varicella Vaccine Live (VVL) or a two-dose adjuvanted Recombinant Zoster Vaccine (RZV).
A multi-cohort static Markov model was developed to follow age cohorts (50–59, 60–69, 70–79 and ≥ 80 years) over their remaining lifetime. Japan-specific data inputs for the model were obtained from Japanese data sources. Age-stratified vaccine efficacy and waning rates were based on published clinical trial data. In the base-case analysis, vaccine coverage was assumed to be 40% for both vaccines, and compliance with second-dose of the RZV vaccine was set to 95%.
Vaccination with RZV was projected to prevent approximately 3.3 million HZ cases, 692,000 cases of postherpetic neuralgia (PHN), and 281,000 cases of other complications, compared with the prevention of 0.8 million HZ cases, 216,000 PHN cases, and 57,000 other complications with vaccination with VVL. The number of individuals needed to vaccinate in order to prevent one HZ case ranged from 6 to 14 using RZV (depending on age and assumed second-dose compliance) and from 21 to 138 depending on age using VVL. By preventing a higher number of HZ cases and its complications, RZV vaccination led to fewer outpatient visits and hospitalizations than vaccination with VVL.
Both vaccines had a positive public health impact compared to no vaccination, but due to its higher vaccine efficacy, RZV demonstrated a superior public health impact compared with VVL.
GlaxoSmithKline Biologicals SA.
Supplementary material 1 (PDF 206 kb)13555_2018_236_MOESM1_ESM.pdf
NIID (National Institute of Infectious Diseases). Infectious Agents Surveillance Report (IASR). 2016. http://www.niid.go.jp/niid/ja/iasr.html. Accessed 30 Nov 2017.
Volpi A. Severe complications of herpes zoster. Herpes. 2007;14[Suppl 2]:35–9. PubMed
Mizukami A, Sato K, Adachi K, et al. Impact of herpes zoster and post-herpetic neuralgia on health-related quality of life in Japanese adults aged 60 years or older: Results from a prospective, observational cohort study. Clin Drug Invest. 2018;38:29–37. CrossRef
ACIP (Advisory Committee on Immunization Practices). 2017. https://www.cdc.gov/shingles/vaccination.html. Accessed 6 Feb 2018.
Curran D, Van Oorschot D, Varghese L, et al. Assessment of the potential public health impact of herpes zoster vaccination. Hum Vaccin Immunother. 2017;13:2213–21. CrossRef
e-STAT (The portal site of Official Statistics in Japan) . https://www.e-stat.go.jp/SG1/estat/eStatTopPortal.do. Accessed 6 Feb 2018.
Shiraki K, Toyama N, Daikoku T, Yajima M, For the Miyazaki Dermatologist Society. Herpes zoster and recurrent herpes zoster. Open Forum Inf Dis. 2017;4:ofx7.
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Eng J Med. 2005;352:2271–84. CrossRef
Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Eng J Med. 2015;372:2087–96. CrossRef
Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Eng J Med. 2016;375:1019–32. CrossRef
Ikematsu H, Yamashita N, Ogawa M, Hirano M, Kovac M, Watanabe D. Efficacy, safety and immunogenicity of a novel adjuvanted subunit herpes zoster vaccine in Japanese aged 50 years and 70 years and older. Kansenshogaku Zasshi. 2018;92:103–14 (in Japanese).
MHLW (Ministry of Health, Labour and Welfare). MHLW vaccination information. http://www.mhlw.go.jp/topics/bcg/other/5.html. Accessed 6 Feb 2018.
Baxter R, Bartlett J, Fireman B, et al. Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study. Am J Epidemiol. 2017;187:161–9. CrossRef
Zhang D, Johnson K, Newransky C, Acosta CJ. Herpes zoster coverage in older adults in the US, 2007–2013. AJPM. 2017;52:e17–23.
Public Health England. Herpes zoster (shingles) immunization programme September 2015 to August 2016. Report for England 2016. https://www.gov.uk/government/publications/herpes-zoster-shingles-immunisation-programme-2015-to-2016-evaluation-report. Accessed 30 Nov 2017.
Varghese L, Curran D, Yan S, Krishnarajah S, Olivieri A. Estimating the potential public impact of introducing the HZ/su vaccine in the US population aged ≥ 50 years. ID Week. 2015. https://idsa.confex.com/idsa/2015/webprogram/Paper52887.html. Accessed 30 Nov 2017.
Varghese L, Nissen M, Olivieri A, Curran D. Public health perspective of phase III results of an investigational herpes zoster vaccine. In: Public Health Association of Australia—Communicable Disease Control Conference 2015, Brisbane. 2015. p 42. https://www.phaa.net.au/eventsinfo/communicable-disease-control-conference-2. Accessed 15 June 2017.
Van Oorschot D, Anastassopoulou A, Schlegel K, Varghese L, von Krempelhuber A, Curran D. The public health impact of a new herpes zoster vaccine to the German population. Value Health. 2016;19:A400–1.
Van Oorschot D, Hunjan M, Varghese L, Canavan C, Curran D. The public health perspective of an investigational herpes zoster vaccine in the United Kingdom (UK). Value Health. 2016;19:400.
Van Oorschot D, Tavares R, Widenmaier R, Varghese L, Curran D. Forecasting the potential public health impact of introducing a new herpes zoster vaccine to the Canadian population. In: Canadian Immunization Conference, Ottawa, 2016, p 12. http://cic-cci.ca/wp-content/uploads/2017/01/CIC16_posterabstracts-1.pdf. Accessed 30 Nov 2017.
Johnson KD, Jiang Y, Goyette A et al. Comparing the estimated potential health impact of two herpes zoster vaccines in Ontario. In: Canadian Immunization Conference 2016, Ottawa, 2016, p 13. http://cic-cci.ca/wp-content/uploads/2017/01/CIC16_posterabstracts-1.pdf. Accessed 30 Nov 2017.
Merck Sharp & Dohme Corp. Prescribing information for ZVL. http://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf. Accessed 6 Feb 2018.
- The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis
Desirée Van Oorschot
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II